Publication details
Retroperitoneální fibróza - diagnostika a léčba
| Title in English | Retroperitoneal fibrosis – diagnosis and treatment |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Rozhledy v chirurgii |
| MU Faculty or unit | |
| Citation | |
| Web | https://perspinsurg.com/rvch/article/view/740 |
| Doi | http://dx.doi.org/10.33699/PIS.2022.101.6.265-271 |
| Keywords | retroperitoneal fibrosis; IgG4 related disease; rituximab; cyclophosphamide |
| Description | Idiopathic retroperitoneal fibrosis (IRF) is a rare condition characterized by the development of a peri-aortic and peri-iliac tissue showing chronic inflammatory infiltrates and pronounced fibrosis. Ureteral entrapment with consequent obstructive uropathy is one of the most common complications which can lead to acute renal failure and, in the long term, to varying degrees of chronic kidney disease. Common symptoms at onset include lower back, abdominal or flank pain. Pain is frequently referred to the hip, to the groin and to the lateral regions of the leg, often with nocturnal exacerbations and not responding to position changes. The disease is commonly associated with signs of systemic inflammatory response (malaise, fever, and anorexia and weight loss). Glucocorticoids are considered the cornerstone of the therapy. The use of other immunosuppressive agents, including cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil and biological agents such as rituximab, tocilizumab and infliximab have been reported as a valuable option mostly in case reports, cases series and small studies. These agents allowed to reduce cumulative dose of glucocorticoids and their adverse effects. Combined therapy is preferable for all patients who suffer from significant glucocorticoid-related toxicity or in cases where glucocorticoids alone are insufficient to treat the condition. |